Attachment II - Ifege 5 
9209-029 
9209 -030 a 
9403-031 
9209-032 
9209-033 
9212-034 8 
9212-035 8 
(M/BM/PB) 
Schuening, Friedrich G.; Fred Hutchinson Cancer Research Center, University of Washington, 
Seattle, Washington; A Trial of G-CSF Stimulated Peripheral Blood Stem Cells for Engraftment in 
Identical Twins. 
RAC Approval: 9-14-92/NIH Approval: 2-5-93 
CLOSED: Protocol Never Initiated 
(M/BM/PB) 
Deisseroth, Albert B.; University of Texas MD Anderson Cancer Center, Houston, Texas; Use of 
Retroviral Markers to Identify Efficacy of Purging and Origin of Relapse Following Autologous Bone 
Marrow and Peripheral Blood Cell Transplantation in Indolent B Cell Neoplasms (Follicular Non- 
Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia) Patients. 
RAC Approval: 9-14-92/NIH Approval: 12-2-93 
Minor Modification: 11-3-93 
Minor Modification: 11-18-93 
Minor Modification: 10-27-94 
(T/C/Non-small Cell Lung Cancer) 
Roth, Jack A.; The University of Texas MD Anderson Cancer Center. Houston. Texas: Clinical 
Protocol for Modification of Oncogene and Tumor Suppressor Gene Expression in Non-Small Cell 
Lung Cancer NSCLC). 
9209-031/ RAC Approval of Original Protocol: 9-15-92/ 
RAC Approval of Original Protocol Withdrawn 12-3-93 
9403-031/ RAC Approval of Resubmitted Protocol: 3-4-94/ 
NTH Approval of Resubmitted Protocol: Pending 
(M/BM) 
Brenner, Malcolm K.; St. Jude Children’s Research Hospital, Memphis, Tennessee: A Phase II Trial 
of the Baxter Neuroblastoma Bone Marrow Purging System Using Gene Marking to Assess Efficacy. 
RAC Approval: 9-15-92/NIH Approval: 2-5-93 
(T/V/C) 
Lotze, Michael T. and Rubin, Joshua T.; University of Pittsburgh, Pittsburgh, Pennsylvania; Gene 
Therapy of Cancer A Pilot Study of IL-4 Gene Modified Antitumor Vaccines. 
RAC Approval: 9-15-92/NIH Approval: 2-5-93 
(T/IGD/Cystic Fibrosis) 
Crystal, Ronald G.; New York Hospital-Comell Medical Center; A Phase I Study, in Cystic Fibrosis 
Patients, of the Safety, Toxicity, and Biological Efficacy of a Single Administration of a Replication 
Deficient, Recombinant Adenovirus Carrying the cDNA of the Normal Human Cystic Fibrosis 
Transmembrane Conductance Regulator Gene in the Lung. 
RAC Approval: 12-3-92/NIH Approval: 4-16-93 
Minor Modification: 5-17-93 
Minor Modification: 10-8-93 
Minor Modification: 11-29-93 
Minor Modification: 2-4-94 
(T/IGD/Cystic Fibrosis) 
Wilson, James M.; University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, and 
Richard H. Simon; University of Michigan Medical Center, Ann Arbor, Michigan; Gene Therapy of 
Cystic Fibrosis Lung Diseases Using El Deleted Adenoviruses: A Phase I Trial. 
RAC Approval: 12-3-92/NIH Approval: 8-26-93 
Minor Modification: 8-17-93 
Minor Modification: 8-26-93 
Minor Modification: 8-31-94 
Recombinant DNA Research, Volume 20 
[493] 
